CytomX Therapeutics (CTMX) Announces Retirement of John A. Scarlett from Board

CytomX Therapeutics, Inc. (Nasdaq: CTMX) today announced that John A. Scarlett, M.D. is retiring from its board of directors, effective when his current term expires at the company’s next annual meeting of stockholders, which is currently scheduled to be held on June 15, 2022.

Dr. Scarlett has served as a member of the CytomX Therapeutics board since June 2016, and is currently chair of the Compensation Committee and a member of the Audit Committee. He also serves as chairman and chief executive officer of Geron Corporation.

“I would like to express my sincere thanks to Chip for his six years of CytomX board service,” said Sean McCarthy, D.Phil., chief executive officer and chairman of the board of directors. “Chip joined us shortly after we became a publicly-traded company and his wide-ranging biopharma experience has been invaluable as CytomX has advanced to an integrated research and development company with a rich pipeline of therapeutic candidates.”

“It has been a pleasure contributing to the maturation and growth of CytomX over the past six years, and I extend my best wishes to the board and management for great future success,” commented Dr. Scarlett.

You May Also Be Interested In

• Heidi L. O'Neill resigns from Lithia Motors board
• HeartSciences (HSCS) files $200M mixed shelf
• Netcapital gets second Nasdaq notice over late financial filings